Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder with an incidence of approximately 1 in 5,000 to 10,000 live births. TSC has various clinical manifestations such as multiple hamartomas in systemic organs, including the skin. Angiofibromas are the most common skin lesions in patients with TSC. Although benign, angiofibromas develop in childhood and puberty, and can be psychosocially disfiguring for patients. Skin lesions in TSC, specifically angiofibromas, have no significant risk of malignant transformation after puberty; thus, they require no treatment if not prominent. However, the presentation of TSC is important owing to its impact on patient cosmesis. Surgical treatment and laser therapy are the mainstream treatments for angiofibromas. Although the evidence is limited, topical mammalian target of rapamycin inhibitors such as sirolimus (rapamycin) are effective in facial angiofibroma treatment. We describe an adult patient with an angiofibroma who had an excellent response to treatment with topical rapamycin after a single session of carbon dioxide (CO2) laser ablation. The patient showed no sign of relapse or recurring lesions for a year. CO2 laser ablation may serve as a new paradigm of treatment for angiofibromas in TSC. Since the selection of laser devices can be limited for some institutions, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO2 device. (Ann Dermatol 31(5) 555∼558, 2019)

-Keywords-
Angiofibroma, CO2 laser, Sirolimus, Tuberous sclerosis complex

INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder characterized by pleomorphic features of systemic organs. The skin is the most commonly affected organ system with up to 90% involvement1. Facial angiofibroma is the main feature of this disease, affecting approximately 75% of patients. Angiofibromas appear in early childhood (ages 2∼5 years) as red papules and increase in number and size throughout puberty2,3.

To date, various treatment modalities for angiofibromas have been proposed, including surgical excision, curettage, dermabrasion, electrocautery, and laser ablation4-7. Despite the use of rigorous approaches to completely remove the lesions, the outcomes have been suboptimal with a high recurrence rate8,9. In addition to improved understanding of the genetic and molecular pathogenesis of the disease, prominent vascular proliferation due to an increased vascular endothelial growth factor (VEGF) level and mammalian target of rapamycin (mTOR) overactivation were noted in angiofibromas. Rapamycin binds to mTOR with high specificity and represses the VEGF output by inhibiting the
hypoxia-inducible factor and endothelial cell proliferation. Additionally, it suppresses T-cell activity and antibody production, resulting in decreased keratinocyte proliferation and inflammation.

The use of topical rapamycin has been proposed and shown successful outcomes for both preventing and reducing angiofibroma lesions. The current general consensus among the considered studies suggests that topical rapamycin is an efficient therapy for facial angiofibromas, providing improvement in 94% of cases. Unlike pediatric patients who can benefit from preventive measures with the early application of topical rapamycin, adult patients with an already fully developed disease that includes nodular lesions report poor outcomes with monotherapy.

We describe the case of an adult patient who showed an excellent clinical response after a single session of carbon dioxide (CO₂) laser ablation and continued use of 0.2% topical rapamycin for maintenance.

**CASE REPORT**

A 20-year-old Korean male previously diagnosed as having TSC was referred to the dermatology department for the treatment of extensive angiofibromas on his face. His DNA test revealed mutations in TSC2. He presented with scattered and grouped lesions of facial angiofibromas of various sizes and thicknesses. Additionally, periungual fibroma and hypomelanotic macules were noted. Regarding the systemic features of the disease, multiple hamartomas of the heart and kidney were noted. One year before visiting Scar Laser and Plastic Surgery center, the patient underwent ablative laser treatment for cheek lesions. However, most of the lesions recurred within a few months during the late pubertal period, and wound healing was delayed for large nodules.

He underwent extensive CO₂ laser ablations for all facial lesions. We used a starting fluence between 100 and 150 mJ of continuous CO₂ pulses (eCO₂™; Lutronic, Goyang, Korea), and multiple passes were performed until the lesions were flattened. To improve the absorption of topical rapamycin and wound healing, a fractional CO₂ laser was additionally applied on the whole face. The treated areas were cooled with ice packs for 10–15 minutes, and topical rapamycin was directly applied. Thereafter, a foam dressing was applied for protection and maintained for 1 day. To minimize the risk of post-inflammatory hyperpigmentation (PIH), sunscreen with broad-spectrum ultraviolet (UV) A and UVB protection was prescribed.

The patient returned to the clinic on the following day without any complication. He was encouraged to use top-
Table 1. Facial Angiofibroma Severity Index (FASI) scores after treatment

| Parameter | FASI score |
|-----------|------------|
|           | Pretreatment | 1 month | 3 months | 6 months | 8 months |
| Erythema  | 2           | 1        | 1        | 0        | 0        |
| Size      | 3           | 2        | 1        | 1        | 1        |
| Extension | 3           | 3        | 3        | 2        | 2        |

...ical rapamycin once a day afterward. He regularly visited the clinic every 2 ~ 3 months, and no sign of recurrence or irritation was noted at 1 year after laser ablation (Fig. 1). We received the patient’s consent form about publishing all photographic materials. Additionally, there were no signs of hypertrophic scarring or delayed wound healing during the follow-up period (Table 1).

DISCUSSION

The advent of topical rapamycin has dramatically changed the paradigm of angiofibroma treatment. However, topical rapamycin monotherapy is insufficient for fully developed lesions in adults. Various types of lasers have been popular options, and many studies have reported successful results with CO₂, copper vapor, argon, pulsed dye, potassium-titanyl-phosphate, and Nd:YAG lasers. For flattened lesions, lasers targeting the vascular structure or melanin pigments may generate sufficient energy to destroy individual lesions with photothermolysis. However, full-thickness ablation of abnormal keratinization and underlying fibrosis is indispensable for bulky lesions. The CO₂ laser is one of the most widely used lasers in dermatology. CO₂ lasers with a 10,600-nm wavelength target the water component of tissues. As a single CO₂ laser can be modulated to cause tissue reactions of incision, excision, vaporization, and coagulation, it can successfully have a debulking effect even for extensive lesions.

Unlike previous reports showing that the CO₂ laser caused hypertrophic scarring in a considerable percentage of patients, we did not experience scarring or delayed wound healing in our patient. This outcome can be partially due to the fractionated application of the CO₂ laser after ablation of single lesions. The ablative fractional CO₂ laser can compensate for the lack of specific photothermolysis in CO₂ laser monotherapy. By thoroughly producing micro-thermal zones on the CO₂-ablated surface, columns of thermal damage cause collagen remodeling and promote wound healing.

PIH can occur at any age and in any skin type, and it has no sex preference. However, this type of hypermelanosis is more common in patients with Fitzpatrick skin types IV ~ VI. Previous research showed that the degrees of erythema and pigmentation correlated linearly after UVB irradiation. Additionally, crusts after laser treatment protect the wound and help prevent the development of PIH after laser treatment. To minimize the risk of PIH, it is necessary to avoid early removal of the crusts and to apply sunscreen with broad-spectrum UVA and UVB protection. We also postulate that topically applied rapamycin could have contributed to normal wound healing after full-thickness ablation. mTOR is a regulator of cell growth and survival, and acts as a mediator of inflammatory and fibrotic processes. In recent in vitro reports, the mTOR signaling pathway was shown to cause proliferation of abnormal fibroblasts, causing pathologic scars. Therefore, topical rapamycin can induce a synergistic effect of angiogenesis inhibition for the recurrence of angiofibroma lesions and abnormal scarring repression after CO₂ laser ablation. Notably, even with a 0.2% preparation, topical rapamycin did not cause immediate irritation when directly applied on the laser-ablated surface.

Angiofibromas in TSC significantly affect patients’ quality of life by causing psychosocial comorbidities. It can be especially burdensome for late adolescent and young adult patients who have already developed extensive lesions throughout puberty. Despite the use of expensive approaches, there is no sustained efficacy in the long term and the risks of complications such as scarring remain. TSC is a predominantly inherited genetic condition that occurs in all races and ethnic groups. We concede with current reports describing the successful outcomes of various laser devices. However, the selection of laser devices can be limited for some institutions. Therefore, we suggest a rather basic but highly effective approach for angiofibroma treatment that can be generally applied with the classic CO₂ device.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

ORCID

Jongwook Oh, https://orcid.org/0000-0001-8516-7894
Jihee Kim, https://orcid.org/0000-0002-0047-5941
Won Jai Lee, https://orcid.org/0000-0003-3056-0503
Ju Hee Lee, https://orcid.org/0000-0002-1739-5956

REFERENCES

1. Schwartz RA, Fernández G, Kotulska K, Jóźwiak S. Tubercous...
sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202.
2. Jóźwiak S, Schwartz RA, Janniger CK, Michalowicz R, Chmielik J. Skin lesions in children with tuberous sclerosis complex: their prevalence, natural course, and diagnostic significance. Int J Dermatol 1998;37:911-917.
3. Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics 2011;127:e117-e125.
4. Bittencourt RC, Huilgol SC, Seed PT, Calonje E, Markey AC, Barlow RJ. Treatment of angiofibromas with a scanning carbon dioxide laser: a clinicopathologic study with long-term follow-up. J Am Acad Dermatol 2001;45:731-735.
5. Fioramonti P, De Santo L, Ruggieri M, Carella S, Federico LT, Onesti MG, et al. Co2/Erbium:YAG/Dye laser combination: an effective and successful treatment for angiofibromas in tuberous sclerosis. Aesthetic Plast Surg 2014;38:192-198.
6. Papadavid E, Markey A, Bellaney G, Walker NP. Carbon dioxide and pulsed dye laser treatment of angiofibromas in 29 patients with tuberous sclerosis. Br J Dermatol 2002;147:337-342.
7. Weiss ET, Geronemus RG. New technique using combined pulsed dye laser and fractional resurfacing for treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med 2010;42:357-360.
8. Balestri R, Neri I, Patrizi A, Angileri L, Ricci L, Magnano M. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex. J Eur Acad Dermatol Venereol 2015;29:14-20.
9. Kavanagh KT, Cosby WN. Shave excision and dermabrasion of midline angiofibroma in tuberous sclerosis. Arch Otolaryngol Head Neck Surg 1986;112:886-888.
10. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006;66:5549-5554.
11. Paghdal KV, Schwartz RA. Sirolimus (rapamycin): from the soil of Easter Island to a bright future. J Am Acad Dermatol 2007;57:1046-1050.
12. Jóźwiak S, Sadowski K, Kotulska K, Schwartz RA. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex—a comprehensive review of the literature. Pediatr Neurol 2016;61:21-27.
13. Tu J, Foster RS, Bint IJ, Halbert AR. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions. Australas J Dermatol 2014;55:63-69.
14. Ma G, Wu P, Lin X, Chen H, Li W, Hu X, et al. Nd:YAG laser for “fractional” treatment of angiofibromas. Int J Dermatol 2014;53:638-642.
15. Pasyk KA, Argenta LC. Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 1988;20:426-433.
16. Tope WD, Kageyama N. “Hot” KTP-laser treatment of facial angiofibromata. Lasers Surg Med 2001;29:78-81.
17. Omi T, Numano K. The role of the CO2 laser and fractional CO2 laser in dermatology. Laser Ther 2014;23:199-233.
18. Tierney EP, Hanke CW, Petersen J. Ablative fractional CO2 laser treatment of photoaging: a clinical and histologic study. Dermatol Surg 2012;38:1777-1789.
19. Ong CT, Khoo YT, Mukhopadhyay A, Do DV, Lim IJ, Aalami O, et al. mTOR as a potential therapeutic target for treatment of keloids and excessive scars. Exp Dermatol 2007;16:394-404.
20. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010;62:2476-2487.